Biocryst Pharmaceuticals (BCRX) Income from Continuing Operations (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has reported Income from Continuing Operations for 17 consecutive years, with $78.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income from Continuing Operations rose 1441.69% year-over-year to $78.4 million; the trailing twelve-month figure through Jun 2026 stood at -$384.7 million (down 977.18% YoY), and the FY2025 full-year result was $263.9 million, up 396.87% from the prior year.
• Income from Continuing Operations advanced to $78.4 million in Q2 2026 per BCRX's latest filing, from -$721.8 million in the prior quarter.
• Across five years, Income from Continuing Operations topped out at $245.8 million in Q4 2025 and bottomed at -$721.8 million in Q1 2026.
• Historically, Income from Continuing Operations has averaged -$52.3 million across 5 years, with a median of -$35.8 million in 2023.
• The widest YoY moves for Income from Continuing Operations: up 1441.69% in 2026, down 2255762.5% in 2026.
• Over 5 years, Income from Continuing Operations stood at -$71.5 million in 2022, then gained by 13.71% to -$61.7 million in 2023, then jumped by 56.59% to -$26.8 million in 2024, then jumped by 1017.5% to $245.8 million in 2025, then tumbled by 68.11% to $78.4 million in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered $78.4 million, -$721.8 million, and $245.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.